Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis

Triple combination of anti-PD-1/PD-L1 immunotherapy and anti-BRAF plus anti-MEK targeted therapy is a promising antitumor strategy and is increasingly being used in clinical trials. To evaluate the safety and efficacy of triple combination of PD-1/PD-L1, BRAF, and MEK inhibition in patients diagnose...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Ye Liu, Xilan Zhang, Guoying Wang, Xinchang Cui
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-06-01
Subjects:	triple combination therapy PD-1/PD-L1 BRAF inhibition MEK inhibition melanoma meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.693655/full